Precipio Inc (PRPO)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$27.40+4.90%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · PRPO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -46.4% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 35.9% |
Growth built into the price is above our model estimate.
The price assumes 82.3 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 33 industry peers · Company calendar date is not available
Why it matters: If management changes its plans, Precipio may not compete as well.
Watch forManagement shares a new plan to improve their market position.
Also watch forManagement says there are no changes to the current plans or priorities.
Why it matters: Revenue growth below the median would signal weakening demand in a growth sector.
Worry ifQ2 revenue growth reported below the median growth rate for the sector.
Less concerning ifQ2 revenue growth remains above the median growth rate for the sector.
Why it matters: Product revenue growth is a sign of market acceptance and operational success. It supports overall revenue growth.
Supportive ifProduct revenue exceeds $1M in Q3-2026, indicating strong demand.
Worry ifProduct revenue stays under $0.9M. This shows weak market performance.
Why it matters: Management wants to lower net losses. If they succeed, it shows better financial health.
Supportive ifNet losses are down compared to Q1-2026. This shows good cost management.
Worry ifNet losses go up or stay the same compared to Q1-2026. This shows ongoing issues.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$215 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $648 loss on $10,000 · 6.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,454 loss on $10,000 · 34.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The earnings call will provide insights into revenue growth and future plans. Investors will look for details on customer growth and product pipeline.
Supportive ifManagement says revenue grew over $7M. They also report good Adjusted EBITDA.
Worry ifManagement does not mention revenue growth. They give a negative view on future performance.
Why it matters: Positive cash flow means the company can pay for operations without outside money. This is key for stability.
Supportive ifCash flow from operations remains positive in Q3-2026.
Worry ifCash flow from operations turns negative in Q3-2026.
Why it matters: If revenue growth picks up, it could signal a positive shift for Precipio in a maturing sector.
Supportive ifHealth Care sector revenue growth is speeding up to 12% year over year.
Worry ifRevenue growth remains below 9% year over year.
Why it matters: Positive Adjusted EBITDA shows better financial health. It helps build investor trust.
Supportive ifAdjusted EBITDA was positive in Q2-2026. This shows better operations.
Worry ifAdjusted EBITDA was negative in Q2-2026. This shows ongoing money problems.
Why it matters: Going over this revenue mark shows growth and strong operations.
Supportive ifQ2-2026 revenue was over $7M, showing strong performance.
Worry ifQ2-2026 revenue was below $7M, hinting at growth problems.
Why it matters: This call will provide insights into revenue growth and business strategy. Investors will look for updates on customer growth and product pipeline.
Supportive ifManagement says customer growth and the pipeline are getting stronger. This was said during the call.
Worry ifManagement fails to address key growth metrics or shows signs of stagnation.